A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: A new tool to decipher their chemoresistance and self-renewal mechanisms

Stem Cells Translational Medicine

Volumn 3, Issue 4, 2014, Pages 520-529

  Griessinger, Emmanuel ^a   Anjos Afonso, Fernando ^a   Pizzitola, Irene ^a   Rouault Pierre, Kevin ^a   Vargaftig, Jacques ^a   Taussig, David ^b   Gribben, John ^b   Lassailly, François ^a   Bonnet, Dominique ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute myeloid leukemia; Leukemia initiating cells; Leukemic long term culture initiating cell; Xenograft

Indexed keywords

CD38 ANTIGEN; CD45 ANTIGEN; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL TISSUE; ARTICLE; CELL RENEWAL; COCULTURE; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG RESISTANCE; EX VIVO STUDY; FEEDER CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PHENOTYPE; STEM CELL NICHE; STEM CELL TRANSPLANTATION; XENOGRAFT; XENOTRANSPLANTATION;

ACUTE MYELOID LEUKEMIA; LEUKEMIA INITIATING CELLS; LEUKEMIC LONG-TERM CULTURE INITIATING CELL; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR CELLS, CULTURED;

EID: 84897535410     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0166     Document Type: Article

References (40)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341:1051-1062.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
3. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-648.
4. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007;25: 1315-1321.
5. Damiano JS, Cress AE, Hazlehurst LA et al. Cell adhesion mediated drug resistance (CAMDR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93: 1658-1667.
6. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-2526.
7. Zhou BB, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
8. Wunderlich M, Mizukawa B, Chou FS et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 2013;121:e90-e97.
9. Taussig DC, Miraki-Moud F, AnjosAfonso F et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008;112:568-575.
10. Taussig DC, Vargaftig J, Miraki-Moud F et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010;115:1976-1984.
11. Sarry JE, Murphy K, Perry R et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgc-deficient mice. J Clin Invest 2011;121:384-395.
12. Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-1093.
13. Rafii S, Shapiro F, Pettengell R et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995;86:3353-3363.
14. Lu LS, Wang SJ, Auerbach R. In vitro and in vivo differentiation into B cells, T cells, and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded. 100-fold by coculture with a clonal yolk sac endothelial cell line. Proc Natl Acad Sci USA 1996;93:14782-14787.
15. Rodan SB, Imai Y, Thiede MA et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 1987;47:4961-4966.
16. Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996;87:518-524.
17. Gillette JM, Larochelle A, Dunbar CE et al. Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nat Cell Biol 2009;11:303-311.
18. van Gosliga D, Schepers H, Rizo A et al. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 2007;35:1538-1549.
19. Ailles LE, Gerhard B, Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997;90:2555-2564.
20. Méndez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-834.
21. Kiel MJ, Yilmaz OH, Iwashita T et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121:1109-1121.
22. Hooper AT, Butler JM, Nolan DJ et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009;4:263-274.
23. Zhang J, Niu C, Ye L et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836-841.
24. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-846.
25. Bruserud O, Ryningen A, Wergeland L et al. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004;89:391-402.
26. Dias S, Choy M, Alitalo K et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002;99:2179-2184.
27. Glenjen NI, Hatfield K, Bruserud O. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. Eur J Haematol 2005;74: 24-34.
28. Liesveld JL, Rosell KE, Lu C et al. Acute myelogenous leukemia-microenvironment interactions: Role of endothelial cells and proteasome inhibition. Hematology 2005; 10:483-494.
29. Danet GH, Pan Y, Luongo JL et al. Expansion of human SCID-repopulating cells under hypoxic conditions. J Clin Invest 2003;112: 126-135.
30. Hammoud M, Vlaski M, Duchez P et al. Combination of low O(2) concentration and mesenchymal stromal cells during culture of cord blood CD34(+) cells improves the maintenance and proliferative capacity of hematopoietic stem cells. J Cell Physiol 2012;227: 2750-2758.
31. Hermitte F, de la Grange BP, Belloc F et al. Very low O2 concentration (0.1%) favors G0 return of dividing CD34+ cells. STEM CELLS 2006;24:65-73.
32. Wang Y, Liu Y, Malek SN et al. Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011;8: 399-411.
33. Chan N, Koritzinsky M, Zhao H et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68:605-614.
34. Comerford KM, Wallace TJ, Karhausen J et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394.
35. Erler JT, Cawthorne CJ, Williams KJ et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-2889.
36. Szilvassy SJ, Meyerrose TE, Ragland PL et al. Homing and engraftment defects in ex vivo expanded murine hematopoietic cells are associated with downregulation of beta1 integrin. Exp Hematol 2001;29:1494-1502.
37. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-3149.
38. Durie BG, Jacobson J, Barlogie B et al. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22:1857-1863.
39. Ardeshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 2003;362:516-522.
40. Huff CA, Matsui W, Smith BD et al. The paradox of response and survival in cancer therapeutics. Blood 2006;107:431-434.